TNF and Cowden disease: Since 1998, when the US Food and Drug Administration approved infliximab (IFX) for treatment of moderate or severe CD that does not respond to a conservative treatment, monoclonal antibodies to tumor necrosis factor alpha (TNF-α) have become the hallmark treatment for refractory CD.